
Opinion|Videos|April 4, 2025
Evaluating the Safety of Topical JAK Inhibitors in the Pediatric Population: Insights into Systemic Risks and Adverse Effects
Author(s)Aaron S. Farberg, MD
Aaron Farberg, MD, discuss how JAK inhibitors have come under scrutiny in the past for systemic adverse effects in oral formulations, while exploring the safety data of topical JAK inhibitors in the pediatric population, which appears to show a more favorable risk profile with localized effects.
Advertisement
This news content has been independently developed and is not endorsed by the American Academy of Dermatology.
Video content above is prompted by the following:
- JAK inhibitors have come under scrutiny in the past for systemic adverse effects in oral formulations. How do you interpret the safety data of topical JAK inhibitors in the pediatric population?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
























